Kathleen Ford, the Chief Operating Officer of Kura Oncology, Inc. (NASDAQ: KURA), executed a sale of 1,813 shares of the company's common stock on January 27, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were disposed of at an average price of $8.4607 per share, producing a gross transaction value of $15,339.
Following the sale, Ford retained direct ownership of 153,560 shares of Kura Oncology common stock. The filing notes that the shares were sold to cover taxes associated with the vesting of a restricted stock unit (RSU) that Ford received on January 26, 2022.
Separately, Kura Oncology has announced commercial progress for its menin inhibitor, KOMZIFTI. The company reported the first U.S. commercial sale of KOMZIFTI, which has triggered a $135 million milestone payment from its partner Kyowa Kirin. Kura expects to receive that payment before the end of the year.
KOMZIFTI, described as an oral menin inhibitor, has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines as a Category 2A recommended option for adults with relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation. That designation follows the U.S. Food and Drug Administration's approval of the drug on November 13, 2025.
Market research firm Citizens has reiterated a Market Outperform rating on Kura Oncology and left its price target unchanged at $24.00. In its commentary, Citizens highlighted potential advantages of Kura's menin inhibitor, ziftomenib, relative to competitors, citing particular relevance for older and more clinically complex AML patients.
Taken together, the insider transaction and the corporate updates reflect concurrent, discrete developments in Kura's equity ownership and its commercial execution in oncology. The sale by the company's COO was explicitly tied to a tax obligation stemming from a prior RSU vesting, while the company continues to advance its product commercialization and to receive external validation from guideline inclusion and partner-triggered milestone payments.